AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
IBRX vs MSFT Fundamental Comparison
| Metric | IBRX | MSFT |
|---|---|---|
| Revenue | $113.3M | $158.9B |
| Net Income | $-351.4M | $66.2B |
| Net Margin | -310.2% | 41.7% |
| ROE | N/A | 16.9% |
| ROA | -70.0% | 10.0% |
| Current Ratio | 5.10x | 1.39x |
| Debt/Equity | N/A | 0.10x |
| EPS | $-0.38 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IBRX vs MSFT: Frequently Asked Questions
Is IBRX or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. IBRX is rated STRONG SELL (92% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does IBRX compare to MSFT fundamentally?
ImmunityBio, Inc. has ROE of N/A vs MICROSOFT CORP's 16.9%. Net margins are -310.2% vs 41.7% respectively.
Which stock pays higher dividends, IBRX or MSFT?
IBRX has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IBRX or MSFT for long term?
For long-term investing, consider that IBRX has STRONG SELL rating with 92% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IBRX vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IBRX vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.